-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A variety of immune checkpoint inhibitors (ICI) are approved for advanced urothelial cancer (UC)
A variety of immune checkpoint inhibitors (ICI) are approved for advanced urothelial cancer (UC)
The study retrospectively included 70 patients with advanced UC who received ICI treatment from 2015 to 2020
The study retrospectively included 70 patients with advanced UC who received ICI treatment from 2015 to 2020
The median age is 69.
High visceral fat index (VFI) was associated with improved PFS (HR: 1.
Prognostic factors
Compared with patients with low-risk scores, OS (HR: 6.
Compared with patients with low-risk scores, OS (HR: 6.
OS
Compared with patients with low bone density, OS (HR: 2.
In summary, studies have shown that body composition can be used as a predictor of efficacy and prognostic markers for patients with advanced urothelial cancer treated with ICI
Original source:
D YLAN J.